Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Boston Scientific detracted after growth slowed in two of its key businesses—its electrophysiology franchise and Watchman heart implant for reducing stroke risk—amid growing competition and mixed clinical trial results. We exited the...
— Benjamin Allen, Todd Ahlsten, Andrew Choi
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Boston Scientific
Boston Scientific ($BSX) represents 5.7% of the fund's portfolio. The company designs,...
A highly innovative pipeline in cardiology and other medtech spaces continues to fuel double-digit revenue growth and operating leverage. Recent stock declines...
More institutional theses from Parnassus Core Equity Fund
Meta Platforms owns leading digital social applications - including Facebook, Instagram, and WhatsApp - reaching billions of global daily active users. The fund initiated...
The manager initiated a new position in AMD after a sharp price correction. The stock provides...
The fund purchased shares of ServiceNow following a substantial decline in price. The firm has...